| 16.05 16:42 | dpa-AFX: Takeda Canada Finalises LoI With PCPA For Antiviral Drug Livtencity |
| 16.05 14:07 | dpa-AFX: *TAKEDA CANADA CONCLUDES LOI WITH PCPA FOR LIVTENCITY IN ADULT POST-TRANSPLANT CMV TREATMENT |
| 13.05 12:36 | dpa-AFX: Takeda, AC Immune Sign License Agreement For Active Immunotherapy For Alzheimer's Disease |
| 13.05 12:05 | dpa-AFX: *AC IMMUNE, TAKEDA SIGN LICENSE AGREEMENT FOR ACTIVE IMMUNOTHERAPY TARGETING AMYLOID BETA FOR ALZHEIMER'S DISEASE |
| 09.05 09:20 | dpa-AFX: Takeda Full-year Profit Declines, But Revenue Ascends |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY CORE OPERATING PROFIT 1.188 TRLN YEN VS. 1.054 TRLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY NET INCOME 317.04 BLN YEN VS. 144.20 BLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY PRE-TAX INCOME 375.09 BLN YEN VS. 52.79 BLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY OPERATING PROFIT 490.51 BLN YEN VS. 214.08 BLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY REVENUE 4.027 TRLN YEN VS. 4.263 TRLN YEN LAST YEAR |
| 09.05 08:07 | dpa-AFX: *TAKEDA PHARMA FY EPS 92 YEN; CORE EPS 484 YEN |
| 09.05 08:00 | dpa-AFX: EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement (english) |
| 09.05 08:00 | dpa-AFX: EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement (english) |
| 09.05 08:00 | EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement |
| 09.05 08:00 | EQS-Adhoc: Takeda Pharmaceutical Company Limited: -2- |
| 26.04 15:00 | dpa-AFX: Takeda Reports Positive CHMP Opinion For Fruquintinib |
| 26.04 14:37 | dpa-AFX: *TAKEDA'S FRUQUINTINIB GETS CHMP OPINION FOR PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER |
| 23.04 13:03 | dpa-AFX: *NEUROCRINE BIOSCIENCES SAYS PHASE 2 SAVITRI STUDY MEETS PRIMARY ENDPOINT IN ADULTS WITH MAJOR DEPRESSIVE DISORDER |
| 22.04 11:12 | dpa-AFX: Takeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programs |
| 22.04 10:13 | dpa-AFX: *TAKEDA, ASTELLAS AND SUMITOMO MITSUI BANKING ANNOUNCE MASTER AGREEMENT TO ESTABLISH JOINT VENTURE COMPANY |
|
|
